Skip to main content

Advertisement

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Fig. 3

Morphometric analysis of tumor xenografts. Sections from PC9T790M xenografts treated with osi (a), osi + pem → osi (b) or osi + cis → osi (c) stained by Masson’s Trichrome to distinguish the fibrotic tissue (greenish) from neoplastic cells (purple). Tumors are encircled by black lines to exclude the skin, adnexa and uninvolved soft tissues. Scale bars = 1 mm. Higher magnifications of the same samples are shown on corresponding lower panels in which the increased amount of collagen deposition after treatment with osi + pem → osi or osi + cis → osi is apparent. Scale bars = 100 μm. Bar graphs showing the quantitative evaluation of tissue composition (neoplastic tissue, fibrosis and necrosis) in tumor xenografts following pharmacological treatment with osi alone or in association with pem (d) or cis (e). *p < 0.05, **p < 0.01 vs osi group; Student’s t-test

Back to article page